Nevro Corp. (NVRO) Director Wilfred E. Jaeger Sells 29,665 Shares
Nevro Corp. (NYSE:NVRO) Director Wilfred E. Jaeger sold 29,665 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $82.54, for a total transaction of $2,448,549.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Wilfred E. Jaeger also recently made the following trade(s):
- On Monday, August 14th, Wilfred E. Jaeger sold 25,255 shares of Nevro Corp. stock. The stock was sold at an average price of $82.40, for a total transaction of $2,081,012.00.
- On Wednesday, August 16th, Wilfred E. Jaeger sold 79,657 shares of Nevro Corp. stock. The stock was sold at an average price of $82.74, for a total transaction of $6,590,820.18.
Shares of Nevro Corp. (NYSE:NVRO) traded up 1.06% during midday trading on Wednesday, hitting $83.31. 563,534 shares of the stock were exchanged. The firm’s market cap is $2.45 billion. Nevro Corp. has a 52-week low of $65.82 and a 52-week high of $106.93. The firm’s 50-day moving average is $82.76 and its 200 day moving average is $85.21.
Nevro Corp. (NYSE:NVRO) last posted its earnings results on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.11. Nevro Corp. had a negative net margin of 14.33% and a negative return on equity of 16.25%. The business had revenue of $78.02 million during the quarter, compared to analysts’ expectations of $77.75 million. During the same period last year, the business posted ($0.31) earnings per share. The company’s revenue for the quarter was up 40.8% compared to the same quarter last year. On average, analysts forecast that Nevro Corp. will post ($1.16) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Nevro Corp. (NVRO) Director Wilfred E. Jaeger Sells 29,665 Shares” was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.watchlistnews.com/nevro-corp-nvro-director-wilfred-e-jaeger-sells-29665-shares/1496539.html.
A number of research firms have commented on NVRO. Morgan Stanley boosted their price target on shares of Nevro Corp. from $87.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 8th. Canaccord Genuity reissued a “buy” rating and issued a $120.00 price target on shares of Nevro Corp. in a research note on Wednesday, July 5th. B. Riley cut shares of Nevro Corp. from a “buy” rating to a “neutral” rating and cut their price target for the stock from $108.00 to $85.00 in a research note on Tuesday, May 9th. Northland Securities reissued a “buy” rating and issued a $96.00 price target on shares of Nevro Corp. in a research note on Tuesday, August 8th. Finally, Zacks Investment Research cut shares of Nevro Corp. from a “hold” rating to a “sell” rating in a research note on Saturday, June 3rd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $100.57.
A number of hedge funds have recently modified their holdings of NVRO. BlackRock Inc. increased its stake in Nevro Corp. by 76,628.7% in the first quarter. BlackRock Inc. now owns 1,575,240 shares of the medical equipment provider’s stock valued at $147,602,000 after buying an additional 1,573,187 shares during the period. Janus Henderson Group PLC purchased a new stake in Nevro Corp. during the second quarter valued at $105,837,000. Jennison Associates LLC increased its stake in Nevro Corp. by 67.5% in the second quarter. Jennison Associates LLC now owns 1,139,119 shares of the medical equipment provider’s stock valued at $84,785,000 after buying an additional 458,925 shares during the last quarter. Wells Fargo & Company MN increased its stake in Nevro Corp. by 63.6% in the second quarter. Wells Fargo & Company MN now owns 973,783 shares of the medical equipment provider’s stock valued at $72,478,000 after buying an additional 378,422 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in Nevro Corp. during the first quarter valued at $26,784,000.
About Nevro Corp.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.